HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

L'Oreal SA

This article was originally published in The Rose Sheet

Executive Summary

Increasing its stakes in its exclusive agents in the U.S. and Canada, Cosmair U.S.A. and Cosmair Canada, to become the leading shareholder in both companies, the French firm announces April 14. The company also will gain complete control of its Swiss agent, Lorsa-Fagel, and will expand its holding in Procasa, its agent in Spain, to 49% from about 18%. L'Oreal will obtain the additional shares of Cosmair U.S.A. and Cosmair Canada from Nestle and Mrs. Bettencourt, the primary shareholders of those firms. L'Oreal will purchase the Lorsa-Fagel and Procasa stakes from Nestle for cash. The transactions are expected to be complete by the end of 1994. In 1993, sales for Cosmair U.S.A. were up 11.6% to $1.3 mil. Cosmair Canada sales were $152.1 mil., Lorsa-Fagel revenues were $87.2 mil. and Procasa sales were $157,343, based on Dec. 31 exchange rates

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel